% | $
Quotes you view appear here for quick access.

POZEN Inc. Message Board

  • play_tow play_tow Mar 28, 2013 10:00 AM Flag

    Roth Capital Today....Buy Pozen...$10 Target

    Pozen (NASDAQ:POZN): POZEN announced that it filed for FDA approval of its proprietary, less gastro-erosive aspirin, causing Roth Capital to believe that the company will probably license the drug or carry out another corporate transaction during the year. The firm keeps its Buy rating and a $10 price target on the stock.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Never trust these pumpers they front run for henge funds. Also never buy but always sell into them useless press releases like yesterday by management. That was released to drum up sheep for management to sell to. In a few weeks you will see the filing that they were sellers again.

6.4799+0.1699(+2.69%)1:49 PMEDT